抗体验证的表位错配决定肾移植失败风险
结果显示HLA I类、DRB1和DQB1的表位错配均为独立预测因素,且与移植肾小球病相关。
要点
- 抗体验证的表位错配是死亡删失移植失败的独立预测因素。
- HLA-DRB1和DQB1表位错配风险高于HLA I类。
- 表位错配亦独立预测移植肾小球病。
核心结论
- 供受体特定HLA表位匹配是降低移植失败风险的可行且临床合理策略。
主要发现
- 在无HLA-DQB1错配的亚队列中,每增加一个HLA-DRB1表位错配的风险比为1.384(95%CI 1.293-1.480)。
- 在无HLA-DRB1错配的亚队列中,每增加一个HLA-DQB1错配的风险比为1.384(95%CI 1.072-1.791)。
- 加拿大队列中,HLA-DRB1表位错配预测移植肾小球病的风险比为5.511(95%CI 1.442-21.080),HLA-DRB1/3/4/5为3.640(95%CI 1.574-8.416)。
临床怎么用
- 肾移植供受体匹配时可考虑抗体验证的HLA表位错配,以评估移植失败风险。
局限性
- 研究为观察性队列,可能存在残余混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To optimize strategies that mitigate the risk of graft loss associated with HLA incompatibility, we evaluated whether sequence defined HLA targets (eplets) that result in donor-specific antibodies are associated with transplant outcomes. To define this, we fit multivariable Cox proportional hazard models in a cohort of 118 382 United States first kidney transplant recipients to assess risk of death-censored graft failure by increments of ten antibody-verified eplet mismatches. To verify robustness of our findings, we conducted sensitivity analysis in this United States cohort and assessed the role of antibody-verified eplet mismatches as autonomous predictors of transplant glomerulopathy in an independent Canadian cohort. Antibody-verified eplet mismatches were found to be independent predictors of death-censored graft failure with hazard ratios of 1.231 [95% confidence interval 1.195, 1. 268], 1.268 [1.231, 1.305] and 1.411 [1.331, 1.495] for Class I (HLA-A, B, and C), -DRB1 and -DQB1 loci, respectively. To address linkage disequilibrium between HLA-DRB1 and -DQB1, we fit models in a subcohort without HLA-DQB1 eplet mismatches and found hazard ratios for death-censored graft failure of 1.384 [1.293, 1.480] for each additional antibody-verified HLA-DRB1 eplet mismatch. In a subcohort without HLA-DRB1 mismatches, the hazard ratio was 1.384 [1.072, 1.791] for each additional HLA-DQB1 mismatch. In the Canadian cohort, antibody-verified eplet mismatches were independent predictors of transplant glomerulopathy with hazard ratios of 5.511 [1.442, 21.080] for HLA-DRB1 and 3.640 [1.574, 8.416] for -DRB1/3/4/5. Thus, donor-recipient matching for specific HLA eplets appears to be a feasible and clinically justifiable strategy to mitigate risk of graft loss.
引用
- Sapir-Pichhadze R, Zhang X, Ferradji A, et al. Epitopes as characterized by antibody-verified eplet mismatches determine risk of kidney transplant loss. Kidney Int. 2019. PMID: 32059998. doi:10.1016/j.kint.2019.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。